Last updated: October 1, 2026
Tambocor is the original brand for flecainide acetate, a Class Ic antiarrhythmic used primarily for rhythm control in selected patients with atrial fibrillation, atrial flutter, and certain supraventricular tachycardias. Its commercial profile has shifted from branded specialty medicine to mature generic drug. The active ingredient remains clinically relevant, but Tambocor has limited standalone revenue visibility, no meaningful current patent barrier, and substantial substitution from generic flecainide and competing antiarrhythmic therapies.
What is Tambocor and how is flecainide used?
Tambocor contains flecainide acetate, a sodium-channel blocker that slows cardiac conduction. The FDA label identifies indications including documented life-threatening ventricular arrhythmias and selected supraventricular arrhythmias, including paroxysmal atrial fibrillation and atrial flutter in appropriate patients. Flecainide is generally used when structural heart disease and significant coronary disease have been excluded or carefully assessed.
The drug is available primarily as oral tablets. Common strengths include 50 mg, 100 mg, and 150 mg. Flecainide is also available as a generic prescription product from multiple manufacturers.
Clinical demand is concentrated in:
- Rhythm-control treatment for selected atrial fibrillation patients.
- Prevention of recurrent paroxysmal supraventricular tachycardia.
- Specialist cardiology and electrophysiology prescribing.
- Selected "pill-in-the-pocket" regimens for episodic atrial fibrillation, usually combined with an atrioventricular nodal blocking agent.
Flecainide is not a broad atrial fibrillation treatment for all patients. Its use is constrained by proarrhythmic risk, particularly in patients with prior myocardial infarction or significant structural heart disease. The Cardiac Arrhythmia Suppression Trial linked Class Ic therapy, including flecainide, with increased mortality in certain post-myocardial-infarction patients, materially narrowing the drug's addressable population [1].
When did Tambocor lose exclusivity?
Tambocor lost practical market exclusivity decades ago. The original US product was approved in the mid-1980s, and generic flecainide entered the market after the expiration of the relevant originator protections.
| Commercial milestone |
Approximate timing |
Market impact |
| FDA approval of Tambocor/flecainide |
1985 |
Established flecainide as a branded antiarrhythmic |
| CAST safety findings |
1989 |
Reduced use in post-infarction ventricular arrhythmias |
| Generic flecainide availability |
Early 1990s |
Began permanent price and share erosion |
| Mature multi-source generic market |
2000s onward |
Shifted volume from brand to low-cost manufacturers |
| Current commercial position |
2020s |
Niche branded recognition with generic-dominated economics |
The precise commercial transition differed by market and formulation. US regulatory and commercial records should be distinguished from international product histories because Tambocor licensing and marketing rights varied by jurisdiction.
What is the Orange Book status of Tambocor?
Tambocor is not protected by an active exclusivity position comparable to a recently approved branded medicine. Flecainide acetate tablets are established products with generic alternatives, and the principal commercial barrier is no longer patent exclusivity.
The FDA Orange Book separates approved products from listed patents and regulatory exclusivity. For an older small-molecule product such as Tambocor, the relevant commercial facts are:
- Generic flecainide products are approved through abbreviated new drug applications.
- The core composition-of-matter protection has expired.
- Any historical formulation or use patents would not prevent ordinary generic tablet substitution.
- Current commercial competition is driven by manufacturing cost, supply reliability, wholesaler access, and contracting.
- There is no biosimilar pathway because flecainide is a chemically synthesized small molecule, not a biologic.
The absence of a meaningful current patent barrier does not eliminate all legal risk. Manufacturers can still face patent litigation involving later-developed delivery systems, combination products, manufacturing processes, or brand-related trade dress. Those risks are distinct from protection for standard flecainide acetate tablets.
How many patents protect Tambocor?
No material active patent estate is generally associated with standard Tambocor tablets in the US market. The original drug's commercial protection was based on historical compound and product rights that expired before the present generic-dominated period.
| Protection category |
Current relevance to standard flecainide tablets |
| Composition-of-matter patent |
Expired |
| Original tablet formulation patents |
Expired or commercially immaterial |
| Method-of-use patents |
No known barrier to ordinary generic use |
| Pediatric exclusivity |
Not a current commercial barrier |
| Orphan-drug exclusivity |
Not applicable to the established product |
| Biologic exclusivity |
Not applicable |
| Manufacturing patents |
Potentially relevant to individual suppliers, not to the whole market |
A generic applicant's principal regulatory burden is demonstrating pharmaceutical equivalence and bioequivalence, not overcoming a live Tambocor compound patent. Paragraph IV litigation therefore has limited relevance to the current standard-tablet market. A future reformulation or long-acting delivery product could create a new patent dispute, but that would be a separate product strategy.
What is Tambocor's FDA regulatory status?
Tambocor and generic flecainide products are prescription medicines regulated under the FDA's small-molecule drug framework. Generic applicants typically rely on the reference product's safety and efficacy findings through the ANDA pathway.
The regulatory profile is mature but clinically restrictive:
- Flecainide has established efficacy for selected rhythm-control indications.
- The product carries prominent warnings regarding proarrhythmic effects.
- Patient selection and baseline cardiac evaluation are important.
- Generic substitution is permitted when state law and payer rules allow it.
- FDA approval does not mean that all products are therapeutically appropriate for every atrial fibrillation patient.
For branded economics, the key regulatory fact is that Tambocor does not have the lifecycle position of a newly approved drug. The FDA-approved active ingredient and dosage forms are well understood, which lowers development risk for generic suppliers and reduces pricing power for the brand.
What is the financial trajectory for Tambocor?
Standalone Tambocor revenue is not publicly reported in a reliable, continuous series. The product has not generally been disclosed as a separately material revenue line by its historical owners or distributors. Any precise current Tambocor revenue estimate would therefore be speculative.
The financial trajectory is better characterized by market stage:
Launch and early growth
Tambocor initially occupied a branded antiarrhythmic market with limited direct competition from newer rhythm-control options. Its value was tied to efficacy in supraventricular arrhythmias and its oral dosing convenience.
Post-CAST contraction
The CAST findings changed the risk-benefit profile of flecainide for ventricular arrhythmia suppression. Use declined in higher-risk patients, and prescribing shifted toward carefully selected patients with supraventricular arrhythmias and without significant structural heart disease [1].
Generic erosion
Once generic flecainide became available, brand pricing power fell. Pharmacies, payers, and hospitals increasingly substituted generic products. The brand's residual commercial value became dependent on physician familiarity, patient continuity, distribution, and occasional brand-prescription preferences rather than exclusivity.
Mature-market economics
Current value is concentrated in the active ingredient rather than the Tambocor trademark. Generic manufacturers compete on:
- Tablet manufacturing cost.
- API sourcing.
- FDA compliance history.
- Supply continuity.
- Wholesaler and pharmacy contracts.
- Ability to avoid or resolve manufacturing disruptions.
- Product availability across multiple strengths.
For a mature generic, a temporary supply shortage can create short-term price increases or share shifts. Those gains are usually unstable because other suppliers can re-enter or expand production if margins support the investment.
What generic entry risks exist for Tambocor?
Generic entry risk is largely realized rather than prospective. The principal commercial risk to Tambocor is continued displacement by generic flecainide.
| Risk |
Current assessment |
Financial effect |
| Additional ANDA approvals |
High historically, ongoing possibility |
Increases substitution and price pressure |
| Brand-to-generic conversion |
High |
Reduces branded unit volume |
| Payer exclusion |
High |
Limits reimbursement and prescribing |
| Manufacturing shortage |
Two-sided |
Can temporarily support or damage brand availability |
| New branded reformulation |
Low unless a differentiated product is developed |
Could create a separate premium market |
| Safety-related label restrictions |
Structural |
Limits total addressable demand |
| Therapeutic substitution |
Moderate to high |
Supports alternatives such as propafenone, sotalol, or ablation |
The main risk is not a single Paragraph IV launch. It is persistent low-cost substitution across the prescription channel.
Which companies compete with Tambocor and generic flecainide?
Competition operates at both the molecule and treatment-class levels.
Direct flecainide competition
Generic flecainide manufacturers compete with one another on price and supply. The market has included large generic companies and smaller contract manufacturers, although manufacturer participation can change over time based on profitability and FDA compliance.
The original Tambocor brand competes less on clinical differentiation than on recognition and continuity. In many settings, the generic product is the economically preferred option.
Therapeutic competition
Flecainide competes with:
- Propafenone, another Class Ic antiarrhythmic.
- Sotalol, a beta-blocking Class III antiarrhythmic.
- Dofetilide, which requires specialized initiation and monitoring.
- Amiodarone, which has broad efficacy but substantial long-term toxicity concerns.
- Catheter ablation for selected atrial fibrillation patients.
- Rate-control strategies using beta blockers, nondihydropyridine calcium-channel blockers, or digoxin.
Direct competitive intensity varies by patient profile. Flecainide is strongest in selected patients with paroxysmal atrial fibrillation and no major structural heart disease. It is weaker in patients who require treatment for persistent disease, have heart failure, or have significant ischemic or structural disease.
What formulations are protected by Tambocor?
Standard immediate-release oral tablets have no commercially meaningful current exclusivity barrier. The main formulation opportunity would be a differentiated product with a clear clinical or adherence advantage, such as:
- Extended-release flecainide.
- A controlled-release product with reduced dosing frequency.
- A fixed-dose combination with an atrioventricular nodal blocker.
- A pediatric formulation.
- A hospital-use injectable or acute-care presentation.
- A delivery system that improves pharmacokinetic consistency.
Such products would require separate development, regulatory review, and potentially new patent filings. They would not automatically restore exclusivity to existing Tambocor tablets. A new formulation would also face bioequivalence, dose-conversion, safety, and commercial adoption hurdles.
What patent litigation affects Tambocor?
There is no widely recognized current US patent litigation that materially blocks generic flecainide tablets. The drug's principal litigation exposure is historical and product-specific rather than an active market-wide dispute.
Potential disputes could arise from:
- Alleged infringement of a new extended-release formulation.
- Manufacturing-process patents.
- API crystallization or polymorph claims.
- Combination claims involving flecainide and another cardiac medicine.
- Labeling or induced-infringement claims involving a patented method of use.
- Product liability claims related to proarrhythmic risk.
These categories do not create a current monopoly over conventional flecainide acetate tablets. They would affect only the accused product, process, or use.
How strong is the Tambocor patent estate?
The patent estate is weak as a current commercial asset because the core protections have expired and generic substitution is established. The product has stronger non-patent characteristics:
- Long clinical history.
- Physician familiarity.
- Defined use in a specialized patient segment.
- Low development uncertainty for generic manufacturers.
- Established reimbursement pathways.
- Multiple available dosage strengths.
Its weaknesses are equally clear:
- No meaningful compound exclusivity.
- Low brand pricing power.
- Safety restrictions that limit population size.
- Generic substitution.
- Competition from other antiarrhythmics and catheter ablation.
- Limited ability to differentiate standard tablets.
The relevant moat is clinical familiarity and supply execution, not intellectual property.
What licensing deals have affected Tambocor?
Tambocor historically changed hands through pharmaceutical commercialization and licensing arrangements associated with its originator and later marketers. Public reporting does not establish a current standalone licensing structure that materially changes the economics of standard flecainide tablets.
Any valuation of a Tambocor-related transaction would need to separate:
- Trademark rights.
- Regulatory approvals.
- Distribution rights.
- Geographic rights.
- Generic or authorized-generic rights.
- Any remaining formulation or manufacturing assets.
For a mature product, a transaction would likely be valued on cash flow from residual brand prescriptions, supply relationships, and geographic access rather than future patent-protected growth.
What generic launch scenarios are most likely?
Base case: continued generic dominance
Generic flecainide remains the primary source of market volume. Tambocor retains limited brand demand from prescriber preference, continuity of care, or channel-specific reimbursement.
Upside case: supply disruption
A manufacturing or API interruption reduces generic availability. The brand or alternate generic suppliers capture temporary volume. The effect depends on inventory duration and the speed of competitor recovery.
Downside case: further brand abandonment
Payers eliminate residual brand coverage, pharmacies default to the lowest-cost generic, and the brand becomes commercially marginal.
Strategic case: differentiated reformulation
A company develops extended-release or combination flecainide. This could create a new branded market, but it would require clinical evidence, regulatory approval, pricing justification, and protection against rapid generic design-around.
What is the geographic coverage of Tambocor?
Flecainide is marketed in multiple countries, but the Tambocor brand's commercial status varies by jurisdiction. The product may be sold as Tambocor, under a local brand, or solely as generic flecainide acetate.
The United States is a mature generic market. European and other international markets also generally have established generic competition, although reimbursement rules, substitution practices, reference pricing, and national authorization status differ. Geographic value therefore depends more on local distribution and reimbursement than on global patent coverage.
Key Takeaways
- Tambocor is the original brand of flecainide acetate, a mature Class Ic antiarrhythmic.
- Its core US exclusivity expired long ago, and generic flecainide dominates the market.
- The drug's commercial use narrowed after CAST because of proarrhythmic risk in certain patients.
- Standalone Tambocor revenue is not publicly disclosed in a reliable current series.
- Current value comes from residual brand demand, supply reliability, and specialist prescribing rather than patent protection.
- Standard flecainide tablets have no meaningful active patent barrier.
- Paragraph IV litigation and biosimilar risk are not major current issues for the conventional product.
- The main commercial threats are generic substitution, payer pressure, therapeutic alternatives, and limited patient eligibility.
- A meaningful growth strategy would require a differentiated formulation, combination product, or new delivery system.
- Temporary supply disruptions can alter market shares but are unlikely to restore durable brand exclusivity.
FAQs About Tambocor Market and Exclusivity
Is Tambocor still sold in the United States?
Tambocor has historically been marketed in the United States, but generic flecainide acetate is the dominant commercial product. Current brand availability can vary by distributor, pharmacy channel, and manufacturer strategy.
Is flecainide a generic drug?
Yes. Flecainide acetate is available as a generic prescription drug. Generic versions are approved through the FDA ANDA pathway and compete directly with the Tambocor brand.
Does flecainide have biosimilar competition?
No. Flecainide is a small-molecule chemical drug, so competitors are regulated as generics rather than biosimilars.
Can a new company obtain exclusivity for flecainide?
A company could potentially obtain protection for a novel formulation, delivery system, combination product, or method of use. That protection would not extend automatically to conventional flecainide acetate tablets.
Is Tambocor used for atrial fibrillation?
Yes. Flecainide is used for rhythm control in selected atrial fibrillation patients, especially those without significant structural heart disease. Patient selection is important because of proarrhythmic risk.
References
-
Echt, D. S., Liebson, P. R., Mitchell, L. B., Peters, R. W., Obias-Manno, D., Barker, A. H., Arensberg, D., Baker, A., Friedman, L., Greene, H. L., Huther, M. L., Richardson, D. W., & The CAST Investigators. (1991). Mortality and morbidity in patients receiving encainide, flecainide, or placebo: The Cardiac Arrhythmia Suppression Trial. New England Journal of Medicine, 324(12), 781-788. https://doi.org/10.1056/NEJM199103213241201
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (2023). Flecainide acetate prescribing information. FDA labeling database. https://www.accessdata.fda.gov/scripts/cder/dailymed/
-
January, C. T., Wann, L. S., Calkins, H., Chen, L. Y., Cigarroa, J. E., Cleveland, J. C., Jr., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., Furie, K. L., Heidenreich, P. A., Murray, K. T., Patel, B. M., Piccini, J. P., Prater, S. P., Price, A. M., Reed, S. D., Tietjens, J. R., & Yancy, C. W. (2019). 2019 AHA/ACC/HRS focused update of the 2014 guideline for the management of patients with atrial fibrillation. Circulation, 140(6), e285-e292. https://doi.org/10.1161/CIR.0000000000000665
